Tag
This article explores how dietary alginate fiber enhances mucosal healing through a microbiota-driven taurine pathway, evidenced by preclinical models and translational clinical insights in ulcerative colitis.
This phase 2b trial demonstrates that oral icotrokinra, targeting the interleukin-23 receptor, significantly improves clinical outcomes in moderate to severe ulcerative colitis compared to placebo.
Antibiotic treatment transiently improves pouchitis by suppressing exotoxin-producing bacteria, but resistant strains quickly re-emerge, driving relapse; targeted microbial approaches are needed for sustained remission.
A multicenter RCT shows proactive home fecal calprotectin monitoring without protocolized treatment escalation does not reduce symptomatic flares in ulcerative colitis remission. More research is needed to optimize biomarker-guided manageme
Bacterial quorum-sensing molecules, especially C6-scAHL, were elevated in long-standing ulcerative colitis and promoted colon tumor growth in mice, suggesting a new microbiome-driven pathway for colitis-associated cancer.
A Danish nationwide study reveals higher genetic risk scores for IBD predict more severe disease courses, including increased surgery rates, stronger medication needs, and worse inflammatory markers in both Crohn’s and ulcerative coli
This report examines the role of Intestinal Ultrasound (IUS) in pediatric Acute Severe Ulcerative Colitis (ASUC). Results from 60 patients show that IUS metrics, specifically colonic wall thickness and the Milan Ultrasound Score, can accura
The SOMA.GUT-RCT investigated a targeted psychological intervention for IBS and UC. While the primary 3-month endpoint showed no significant symptom reduction compared to standard care, exploratory data revealed significant psychological im
A Phase 1 trial of SOR102, a first-in-class oral bispecific antibody targeting TNF and IL-23, demonstrates favorable safety and preliminary clinical activity in patients with ulcerative colitis, suggesting a potential shift toward localized
A phase 3 randomized trial in East Asia found oral etrasimod 2 mg superior to placebo for induction and maintenance of clinical remission in moderate–severe ulcerative colitis, with manageable safety and notable ALT elevations.
The EASI trial compared a once-daily 1600 mg 5-ASA tablet with the conventional three 800 mg tablet regimen for ulcerative colitis, finding similar adherence and relapse rates, suggesting a feasible simpler alternative.
Recent research elucidates how smoking modulates gut microbiota and immune responses differently in ulcerative colitis and Crohn’s disease, explaining its protective effect in UC but detrimental role in CD.
The TUSCANY-2 phase 2b trial evaluated afimkibart, a novel anti-TL1A antibody, in moderately-to-severely active ulcerative colitis, demonstrating favorable safety and clinically meaningful remission rates using modified Mayo scores despite
Achieving disease clearance early after induction therapy with ustekinumab in ulcerative colitis patients predicts sustained clinical remission, symptom control, and improved quality of life over four years.
Cyclosporin demonstrated high clinical response rates in adults with severe steroid-refractory ulcerative colitis, allowing over half to avoid colectomy and highlighting its role as an effective rescue therapy.
Interim data from the U-ACTIVATE study demonstrate sustained clinical and endoscopic remission and a consistent safety profile for upadacitinib up to 3 years in moderate to severe ulcerative colitis.
The ACCURE trial demonstrates that laparoscopic appendicectomy combined with standard medical therapy significantly lowers 1-year relapse rates compared to medical therapy alone in ulcerative colitis patients in remission.
A machine learning model using nationwide registry data accurately predicts long-term remission in refractory ulcerative colitis and identifies key prognostic factors such as pseudopolyps.
Phase 3 studies demonstrate guselkumab’s efficacy and safety as induction and maintenance therapy for moderate-to-severe Crohn’s disease and ulcerative colitis, with superiority over placebo and favorable safety profiles.
Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.
